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Monitoring people on antiretroviral therapy (ART) cost-effectively is crucial for the sustainability of ART programmes in sub-Saharan Af-rica. In most countries, patients are required to attend clinics every 
1 to 3 months for clinical assessment. The cost of which — for personnel, in-
frastructure and maintenance — is comparable with costs of the antiretro-
viral drugs themselves1–3. In most settings, patients are monitored by a CD4 
count measurement every 6 months with clinical observation at least every 
3 months, but they are rarely switched to second-line regimens. A reduction 
in visit frequency for patients who do not require an adherence intervention 
or a switch to second-line ART would benefit programmes by reducing costs 
and benefit patients by saving travel costs and time away from work, possibly 
lowering the rate of default from care4. 
The biomarker that most directly measures the ongoing effect of ART is 
the HIV RNA level in plasma (the viral load). If viral load is suppressed, this 
indicates that the patient is adhering to the drug regimen and does not carry 
drug-resistant virus. Data from high-income countries suggest that after 1–2 
years of ART with viral-load suppression the visit frequency can be reduced. 
If the viral load is not suppressed this suggests that there is a need for im-
proved adherence and/or a switch in regimen. In most countries in sub-Saha-
ran Africa, measurement of viral load is not widely available. Quantification of 
HIV RNA requires sophisticated facilities and skilled staff and the costs have 
been high, although costs have substantially decreased in the past 5 years5,6. 
Modelling studies have indicated that there is a benefit to viral-load monitor-
ing compared with monitoring strategies based on the CD4 count or clinical 
observation7–16, but viral-load monitoring has not been found to be cost-ef-
fective7,10–14, owing to the cost of viral-load tests and second-line regimens. 
Currently, the most feasible approach to begin to measure viral load in many 
countries is to collect samples as dried blood spots (DBS). DBS are stable at 
ambient temperature and can be prepared from capillary whole blood, elim-
inating the need for phlebotomy services15. Using existing networks for early 
infant HIV diagnosis, they can be transported to a regional or national labora-
tory with results subsequently returned to the clinic by, for example, mobile 
phone text messaging. However, the presence of cells and low sample volume 
in DBS specimens means that sensitivity and specificity for detecting wheth-
er the level is above the 1,000 copies per millilitre threshold that is used to 
define viral suppression are imperfect and it is unclear if the approach is ad-
equate5,16–27. Looking to the future, it is anticipated that point-of-care (POC) 
tests — tests that enable a decision to be made about patient management 
during the same visit that the sample is taken — may become widely availa-
ble28, and this may result in greater accuracy than the use of DBS, as well as 
facilitating rapid action based on the test result.
In the light of these issues, we consider how HIV treatment programmes 
in low-income countries in sub-Saharan Africa should monitor patients on ART 
in a way that is likely to lead to the greatest population health gains from the 
limited resources available29. We update a model previously used to compare 
monitoring strategies, incorporating new lower costs and the potential for vi-
ral-load-informed ‘differentiated care’ based on reducing clinic visit costs by 
reducing visit frequency among virally-suppressed individuals30,31. 
METHODS
The HIV Synthesis transmission model is an individual-based stochastic mod-
el of heterosexual transmission, natural history, clinical disease and treatment 
of HIV infection that incorporates use of specific drugs, resistance mutations 
and adherence8,32–36.
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ART programme and monitoring strategy modelling 
We based our simulated population around that of Zimbabwe and the under-
lying model is described in detail in the Supplementary Information. We as-
sumed that up to 2015 a CD4 count monitoring strategy has been used. Then 
we considered the introduction of plausible alternative monitoring strategies 
and predicted outcomes over 20 years to 2035. The seven main monitoring 
strategies compared (Table 1) cluster into three main types: clinical observation 
(with or without targeted CD4 count or viral-load testing in those with clini-
cal disease), regular CD4 count monitoring or regular viral-load monitoring. In 
the case of viral-load monitoring, we simulate a strategy consisting of off-site 
laboratory-based testing of DBS using the World Health Organization (WHO) 
recommended 1,000 RNA copies (cps) ml−1 threshold. Viral load measured 
as <1,000 cps ml−1 in the past year is assumed to lead to a reduction in non-
ART programme costs owing to fewer clinic visits by people on first-line ART. 
Measurement of viral load 1,000 cps ml−1 or more is assumed to lead to a tar-
geted adherence intervention, which increases adherence in some people. We 
refer to this strategy as viral-load-informed differentiated care. Regardless of 
the monitoring strategy used, once strategy-specific failure criteria are met 
we assume a probability of switching to a second-line regimen of 0.5 per 3 
months. In practice, current switch rates are lower than this, even in settings 
with viral-load monitoring in place37–39; we chose this higher probability, howev-
er, to be able to discern differences in effects between strategies. In sensitivity 
analyses we consider a situation in which switch rates are zero. Throughout, we 
assume monitoring is performed only for people on first-line ART. 
We model decreased precision of DBS for measuring viral load by con-
sidering the presence of HIV RNA in cells and the small sample volume5,25,40, 
such that the sensitivity and specificity of the measure for detecting viral load 
of >1,000 cps ml−1 compared with measurement on a plasma sample are 86% 
and 92%, respectively (compared with values ranging from 81% to 85% sensi-
tivity and 88% to 99% specificity5 for most assays); we consider other values 
in sensitivity analysis. We also assume that there is a 3-month delay in the 
clinician acting on the result, even though results are generally returned to the 
clinic quicker than this.
Sensitivity analyses were performed to consider: possible differences in 
population adherence profile, potential increases in sexual behaviour, chang-
es in effectiveness of the adherence intervention triggered by viral load being 
>1,000 cps ml−1, a policy of initiation of ART at diagnosis, that visit frequency 
might be reduced in those with a CD4 count of >350 per mm3 in the past year, 
a zero rate of switch to second-line regimens, differences in the baseline prev-
alence of HIV, differences in the proportion on ART, differences in the rate of 
ART interruption if visit frequency has been reduced owing to viral load being 
<1,000 cps ml−1, a higher discount rate of 5% rather than 3%, and a 10-year 
rather than a 20-year time horizon. In addition, we considered the effects of 
whether whole blood or plasma is used, whether the test is done in a central 
laboratory and incurs the 3-month delay in action or is done at POC with no 
delay, the threshold to define failure (200, 1,000 or 5,000 cps ml−1, which is 
only assessed in the context of plasma), and the frequency of measurement 
(every 6 months, annually or every 2 years). 
Last, we focussed on the specific comparison between viral load using 
DBS and using a plasma-based POC test to quantify the extent of various po-
tential advantageous features of a POC test on its cost-effectiveness in rela-
tion to use of DBS. It is important to note that we are considering potential 
features of a POC test — it is not clear that such features can be delivered, 
so this analysis is directed mainly towards developers and should not be in-
terpreted as indicating that POC tests will prove to have any of these advan-
tageous features. This is why we chose to consider a plasma-based POC test, 
although in reality it may be more likely that a whole-blood-based test is used 
for many POC tests, to avoid a plasma separation step. Further details of how 
all these aspects are modelled are provided in the Supplementary Information. 
Economic analysis 
Our objective is to maximize population health — the health benefits as-
sociated with the alternative monitoring strategies are estimated using the 
metric disability-adjusted life years (DALYs) averted — with the available 
resources. A health sector perspective has therefore been adopted for the 
analysis. Direct and indirect costs incurred by the patients are excluded. Both 
costs and health benefits were discounted to present value using a 3% per 
annum discount rate in our base case. The expected costs and health out-
comes associated with each monitoring strategy can be compared to indicate 
which is likely to represent the best value from the available resources. The 
cost-effectiveness threshold for a country represents the opportunity costs of 
resources required to fund the intervention, in terms of the health gains that 
those resources could generate if used for alternative purposes in the public 
health-care system41. As such, the threshold for a country is not readily appar-
ent, but US$500 per DALY averted is likely to be at the upper end based on 
the magnitude of benefit if the resources were spent on other programmatic 
priorities such as eliminating coverage gaps for ART if these are large42. The 
modelling results are intended to inform decisions in sub-Saharan African 
countries such as Zimbabwe classified as low and low-middle income using 
the World Bank country classifications that have typically struggled to scale-
up viral-load monitoring31. The analyses may also be informative for higher 
income countries in the region (such as South Africa and Botswana) that have 
already scaled up viral-load monitoring, but are seeking more efficient ways 
to deliver ART. 
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Figure 1 | Overall programme costs. Costs in US$m per 3 months, 
according to monitoring strategy (mean 2015–2034, discounted at 3% per 
annum from 2015). ART, antiretroviral therapy; VL, viral load; WHO, World 
Health Organization.
Figure 2 | Cost-effectiveness. Cost-effectiveness plane showing clinical- and 
CD4-based monitoring strategies along with viral-load-informed differentiated 
care using dried blood spots. DALYs, disability-adjusted life years; ICER, 
incremental cost-effectiveness ratio.
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Disability weights to calculate DALYs averted were derived from a recent 
comprehensive study43. Unit costs (in US$ at 2014 prices) are detailed in the 
Supplementary Information. In brief, costs of viral-load assays are assumed to 
be $22. This is a fully-loaded cost, counting all components such as reagents, 
costs of equipment, human resources, buildings, and so on (see Supplementa-
ry Information). Because POC viral-load tests are not yet available it was not 
possible to calculate the cost so we assumed a similar cost of $22, although it 
is likely that the fully-loaded cost will be higher than this. The cost of measuring 
CD4 counts is assumed to be $10 (ref. 44). The current annual cost (including 
supply chain) of the first-line regimen of efavirenz, emtricitabine and tenofovir 
(assumed to be used as a fixed-dose combination) is assumed to be $144 per 
person per year and for the second-line regimen of zidovudine, emtricitabine 
and ritonavir-boosted atazanavir to be $312 per person per year45. Annual pro-
gramme costs for clinic visits (not including drug, or viral load or CD4 count 
tests) are $80 per year1,2, with an assumed reduction to $40 per year, after 
measurement of viral suppression because of reduced clinical visit frequency 
of every 6 months from every 1 to 3 months (with interim pharmacy-only vis-
its, depending on the amount of drug that can be dispensed). 
RESULTS
The status of the simulated population in 2014 is shown in Table S1 in Mod-
elling Methods in the Supplementary Information. Mean predicted out-
comes over 20 years are shown in Table 2. The proportion of people who are 
taking or have taken ART (ART-experienced), who have fulfilled the criteria 
for failure of first-line ART is Iowest with no monitoring and is below 15% 
for each of the clinical monitoring strategies. It is highest for the CD4 count 
monitoring (WHO) strategy (41%) because the failure definition is fulfilled 
if the CD4 count is below the pre-ART baseline level (which can occur due 
to high CD4 count variability, and particularly if ART has been interrupted). 
The proportion is intermediate for the CD4 count monitoring (<200) strate-
gy and viral-load-informed differentiated care using DBS strategies (at 26% 
and 27%, respectively). The proportion of all people on ART who have viral 
suppression is highest with the viral-load-informed differentiated care using 
DBS strategy (86%) and lowest with no monitoring (76%), with the small 
range of 10% reflecting the generally high levels of adherence (although we 
consider in sensitivity analyses a situation in which adherence levels are 
lower and the proportion with viral suppression is accordingly lower). The 
death rate is markedly lower for the CD4 count and viral-load monitoring 
strategies than for the other strategies, and this is particularly evident in 
those among whom viral-load failure has occurred. Notably, there is also 
a benefit of viral-load-informed differentiated care using DBS on HIV inci-
dence over all the other strategies.
Costs and their components by monitoring strategy are shown in Fig-
ure 1. Programme costs for clinic visits are lowest with viral-load-informed 
differentiated care using DBS owing to the reduction in clinic visit frequen-
cy among virally-suppressed people. Figure 2 shows the cost-effectiveness 
plane, showing the total incremental DALYs averted in the population over 
20 years, together with the incremental costs (both discounted), compared 
with no monitoring. Owing to the higher death rate of people on ART and 
higher HIV incidence, the clinical monitoring strategies avert fewer DALYs 
than the viral load and CD4-count-based monitoring strategies. Additional 
costs incurred are highest for CD4-count monitoring, particularly the CD4 
count monitoring (WHO) strategy. Viral-load-informed differentiated care 
using DBS averts a similar number of DALYs as CD4-count monitoring and 
is the most cost-effective strategy owing to the reduction in non-ART pro-
gramme costs in people with viral suppression, with an incremental cost-ef-
fectiveness ratio (ICER) of $326 per DALY averted. Figure 3 depicts how 
the cost-effectiveness is affected by the assumed costs of viral-load tests 
and savings in clinic visit costs in people with suppressed viral load. In our 
base case viral-load test cost of $22, viral-load-informed differentiated care 
is cost-effective only if reduced clinic visits provide at least a $30 per person 
per year saving offset.  
The effect of varying model assumptions are shown in Figure 4 and Sup-
plementary Figure 1. Changes in the sensitivity and specificity of viral-load 
measurement using whole blood (as used for DBS) did not markedly influ-
ence the ICER, nor did the extent of the assumed effect of viral-load meas-
urement >1,000 cps ml−1 on adherence. The ICER for viral-load-informed 
differentiated care was lower when we assumed lower population adher-
ence and when we assumed higher population levels of unprotected sex, 
resulting in higher HIV incidence. In a scenario with a switch rate of zero, 
viral-load-informed differentiated care was cost saving. Confirming the re-
sults shown in Figure 3, if no reduction in visit frequency is assumed with vi-
ral-load monitoring (Supplementary Fig. 1u) then it is not cost-effective. The 
only other scenarios in which viral-load-informed differentiated care was not 
cost-effective was when we considered a 10-year time horizon instead of 20 
years and when we considered a doubling of rate of ART interruption in peo-
ple with a reduced visit frequency owing to viral load being <1,000 cps ml−1 
(Figure 4 and Supplementary Fig. 1q and r).
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What the monitoring 
strategy entails for people 
on first-line ART
NA Check on presence 
of symptoms every 3 
months
Check on presence 
of symptoms every 3 
months
Measure viral load 
if WHO 4 condition 
diagnosed or two 
WHO 3 conditions 
diagnosed in 1 year
Check on presence 
of symptoms every 3 
months
Measure CD4 count 
if WHO 4 condition 
diagnosed or two 
WHO 3 conditions 
diagnosed in 1 year.
6-month CD4 count
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measure to confirm 
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count)
12-month CD4 count
 
If failure criteria 
seem to be met, re-
measure to confirm 
(confirmatory CD4 
count)
Viral load measure using 
DBS at 6 months, 12 months 
and every 12 months 
thereafter
If viral load is >1,000 cps 
ml−1 then provide adherence 
intervention and re-measure 
viral load 3 months later 
(confirmatory viral load 
measure)
No CD4 count 
measurements
Failure criteria NA WHO 4 condition 
diagnosed or two 
WHO 3 conditions 
diagnosed in 1 year
Viral load >1,000 
cps ml−1
CD4 count <250 mm−3 CD4 count less than 
pre-ART baseline 
or CD4 count <100 
mm−3 in confirmatory 
CD4 count
CD4 count <200 
mm−3 after more than 
3 years on ART.  CD4 
<100 mm−3 after more 
than 1 year on ART 
in confirmatory CD4 
count
Viral load >1,000 cps ml−1 
in confirmatory viral load 
measure
Reduction in clinical visit 
frequency and hence 
reduction in non-ART 
programme cost*
None None None None None None Yes, when most recent 
viral load  <1,000 cps ml−1, 
measured in the past year
*Assuming 3-monthly clinical visits for all strategies except under viral-load-informed differentiated care when the most recent viral load <1,000 cps ml−1, measured in past year. More frequent clinical visits than 
once every 3 months are not modelled as the model advances in 3-month periods. ART, antiretroviral therapy; Cps, copies; DBS, dried blood spot; WHO 4, World Health Organization stage 4 condition.
Table 1 | The seven main monitoring strategies modelled listed by the short name given to the strategy. 
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In the base case we have considered there to be a switch rate of 0.5 
per 3 months after the strategy-specific failure criteria have been met. In 
practice, in most settings, despite CD4 counts being measured, switching 
rates are much lower than this. We compared use of the CD4 count mon-
itoring (WHO) strategy with a low switch rate of 0.05 per 3 months (the 
current situation in many countries) with viral-load-informed differentiated 
care with a switch rate of 0.5 per 3 months (Fig. 5). The results suggest that 
introduction of the viral-load-informed differentiated care using DBS accom-
panied by a high switch rate would lead to a substantial improvement in 
DALYs averted with a potential reduction in cost, compared with the current 
situation. In the simulated model population of Zimbabwe, over 20 years the 
CD4 count monitoring (WHO) strategy averts 540,000 DALYs compared 
with no monitoring at a cost of $500 million, whereas viral-load-informed 
differentiated care using DBS averts 1.12 million DALYs compared with no 
monitoring at a cost of $361 million. 
We also consider only the viral-load-informed differentiated care strat-
egy and assess the effect of variations in various aspects (Fig. 6); whether 
whole blood or plasma is used, whether the test is POC (central laboratory 
testing using whole blood is our DBS scenario above), the threshold to define 
failure (200, 1,000 or 5,000 cps ml−1, which is only assessed in the context 
of plasma), and the frequency of measurement (every 6 months, annual-
ly or every 2 years). Monitoring every 6 months instead of annually averts 
more DALYs, but does not seem to be cost-effective at the $500 threshold 
(ICER = $1,234). Less frequent monitoring (such as every 2 years) would be 
cost-effective if it were to avert a similar number of DALYs to monitoring 
every year. However, implementing differentiated care based on viral-load 
monitoring as infrequently as every 2 years is currently untested and the po-
tential health consequences are unknown, so this strategy is excluded from 
the comparison (Fig. 6a). Using the 5,000 cps ml−1 threshold also averts 
DALYs at a similar ICER to the 1,000 cps ml−1 threshold, but with reduced 
total benefit. Use of a whole blood sample (for example, DBS) instead of a 
plasma sample is not predicted to result in a marked difference in cost in-
curred (assuming the same unit cost per test) and a modest (4%) benefit in 
DALYs averted. There is a small (6%) predicted benefit of POC testing over 
laboratory monitoring in DALYs averted owing to the fact that the 3-month 
delay is avoided.
DISCUSSION
Our results suggest that viral-load-informed differentiated ART care, using 
DBS sampling if necessary, is likely to be cost-effective in low-income set-
tings in sub-Saharan Africa and is a sustainable model for providing ART. That 
said, the level of savings that result from reduced clinic visits and that can be 
realized in practice with differentiated care are, so far, uncertain and require 
monitoring. The level of savings required depends partially on the cost of vi-
ral-load testing. With the viral-load test cost of $22 as used in our base case, 
an annual saving of at least $30 per year in those with viral suppression is 
required for viral-load-informed differentiated ART care to be cost-effective. 
Given that annual non-ART-programme costs average around $80 per year2 
if patients are being seen every 1 to 3 months, a reduction in visit frequency 
to once every 6 months, and perhaps for long-term suppressed patients to 
every 9 to 12 months, should enable such savings. There is little evidence that 
patients seen at sites with higher non-ART-programme costs have better out-
comes2. We estimate, based on modelling of Zimbabwe over 20 years, that 
in contrast to the current situation in many countries (CD4 count monitor-
ing with low switch rates), introduction of viral-load-informed differentiated 
care would more than double the number of DALYs averted compared with 
no monitoring (1.12 million compared with 0.54 million) and deliver these at 
reduced costs ($360 million compared with $500 million). 
A reduction in the frequency of clinic visits could also affect patients’ ad-
herence to ART and retention in care. There is evidence that some patients 
default from care because they are unable to keep up with the intensive 
clinic visit schedule owing to travel time and cost, and loss of work time4. 
No monitoring Clinical 
monitoring
Clinical 
monitoring 
viral load 
confirmation
Clinical 
monitoring 
CD4 count 
confirmation
CD4 count 
monitoring 
(WHO) 
CD4 count 
monitoring 
(<200)
Viral-load-
informed 
differentiated 
care using DBS
Percentage of ART-
experienced people who 
have fulfilled criterion for 
failure of first-line ART 
7% 14% 10% 13% 41% 26% 27%
Percentage of ART-
experienced people who 
have started second-line 
ART 
3% 13% 10% 13% 38% 24% 25%
Percentage of people 
on ART who have (true) 
viral load <1,000 cps ml-1 
(mean; over 20-year time 
horizon)
76% 79% 78% 79% 85% 82% 86%
Death rate (per 100 
person years) among 
people on ART
4.43 3.63 4.06 3.67 3.02 3.07 3.18
Death rate (per 100 
person years) among 
people with HIV
5.45 4.91 5.2 4.93 4.36 4.43 4.47
Death rate (per 100 
person years) in the 
whole adult population
1.69 1.63 1.66 1.63 1.56 1.58 1.57
Death rate (per 100 
person years) among 
people on ART who 
have virologically failed 
first-line ART (regardless 
of whether monitoring 
strategy has detected it)
9.94 7.5 8.66 7.62 5.53 5.79 5.85
Incidence of HIV (per 100 
person years)
0.84 0.81 0.83 0.81 0.76 0.79 0.73
For each model run for each strategy, the outcome of interest (as listed in the first column) is output for each 3-month period between 2015–2035. Over 500 model runs are done for each strategy, then means 
are taken over 3-month periods and model runs. ART, antiretroviral therapy; Cps, copies; DBS, dried blood spot; WHO, World Health Organization.
Table 2 |  Outcomes over 20 years (2015–2035) in people with HIV (age 15–65), according to monitoring strategy. 
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Notably, retention in care was more than 90% at 4 years among individ-
uals enrolled in community ART clubs in Mozambique, owing, in part, to 
community-based adherence support, decreased travel requirements and 
patient preference46,47. We did not include in our model any such adherence 
or retention benefits associated with differentiated care. There is also the 
possibility that patients may feel less connected to care with a differentiated 
care model, and this might have adverse consequences for adherence and 
retention, although so far there is little evidence to suggest this.  
When using the CD4 count to monitor people on ART, the WHO- 
recommended approach has been to define failure by a CD4 count of 
<100 cells mm−3 of blood or a decline from pre-ART baseline. Our modelling 
suggests that, given the high variability in CD4 count and the fact that it is 
not uncommon for people to interrupt ART for periods of time, this latter 
component results in low specificity and in many patients with viral suppres-
sion being incorrectly categorized as failing and hence switched unnecessar-
ily. The alternative approach we evaluated, similar to that used in the DART 
trial48, is to define failure based on a CD4 count of <100 mm−3 in years 1–3 
on ART, and a CD4 count <200 mm−3 thereafter. This approach performed 
well in our modelling in terms of the death rate of people on ART (as it did 
in the trial itself), although it still resulted in a lower rate of viral suppression 
and hence a higher HIV incidence than with viral-load monitoring, result-
ing in poorer overall effectiveness. In settings that continue to have a CD4 
count capacity, but not viral-load capacity, this suggests that the CD4 count 
monitoring (<200) strategy should be used until viral-load-informed differ-
entiated care is introduced.
The requirement for frequent clinic visits is partially driven by short-
ages of ART supplies at a national level, resulting in clinic level rationing of 
ART quantities dispensed to patients at each visit. Increasing country buffer 
stocks, as well as improving forecasting of need, could enable longer drug 
supplies to be prescribed. However, even if it is not possible to prescribe 
more than a 1–2 months supply of drugs, various approaches can be consid-
ered to prevent patients from having to make frequent pharmacy-only visits 
to clinic46,47,49–54. These include community ART groups, whereby one person 
picks up the drugs for all the members or situations in which patients can 
pick up medicines in a shop or other non-clinical setting55. Other hurdles to 
overcome in adopting viral-load-driven reductions in frequency of clinical 
visits include obtaining buy-in from Ministries of Health for any required 
task shifting, and provision of human resources for dedicated adherence 
support for people with high viral load. In addition, support from professional 
associations of clinical, nursing and pharmacy staff will be important.  
The fact that the viral load is a direct measure of the ongoing effect 
of treatment means it provides an ideal means to differentiate care provi-
sion. However, given the wider availability of CD4 count tests, it might be 
suggested that the CD4 count could be used instead. For example, vis-
it frequency for people with a CD4 count of more than 350 mm−3 could 
be reduced. This would result in a similar reduction in clinic visit costs to 
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Figure 3 | Viral load cost-effectiveness. Indication of whether viral-load-
informed differentiated care is the most cost-effective monitoring strategy 
according to cost of viral load tests and reduction in non-antiretroviral (ART) 
programme costs in people with viral suppression. In the context of cost-
effectiveness threshold US$500. Colours indicate which monitoring strategy 
is economically preferred.
Figure 4 | Incremental cost-effectiveness ratio (ICER) for viral-load-informed 
differentiated care using dried blood spot (DBS) (compared with next less ef-
fective strategy on the efficiency frontier) according to changes in assumptions 
(see Supplementary Figure 1). a, DBS sensitivity 96% and specificity 79% for 
1,000 copies per millilitre threshold (versus plasma). b, DBS sensitivity 71% and 
specificity 97% for 1,000 cps ml−1 threshold (versus plasma). c, DBS sensitivity 
88% and specificity 93% for 1,000 cps ml−1 threshold (versus plasma). d, DBS 
sensitivity 85% and specificity 79% for 1,000 cps ml−1 threshold (versus plasma). 
e, Poorer population antiretroviral therapy (ART) adherence profile such that 
proportion with viral suppression with no monitoring/no second-line ART is 
68% compared with 76% in base case and HIV incidence is 0.96 per 100 person 
years compared with 0.84 in base case. f, Future greater increase in sexual 
behaviour in population such that HIV incidence is 1.46 per 100 person years 
compared with 0.84 in base case. g, Permanent increase in adherence as a result 
of viral load measurement alert in none rather than 40%. h, Permanent increase 
in adherence as a result of viral load measurement alert in 100% rather than 
40%. i, Policy of initiation of ART at diagnosis. j, Reduced frequency of visits if 
CD4 count measured >350 in past year. k, Switch rate of 0 (so only benefit of 
monitoring is to inform who should be seen less frequently). l, Lower prevalence 
of HIV in 2014 (6% instead of 15% in base case). m, Higher prevalence of HIV 
in 2015 (33% instead of 15% in base case). n, Lower proportion on ART in 2015 
(33% instead of 56% in base case). o, Higher proportion on ART in 2015 (70% 
instead of 56% in base case). p, 5% discount rate instead of 3%. q, Ten year time 
horizon instead of 20 year. r, Two times higher rate of ART interruption if visit 
frequency has been reduced due to viral load being <1,000 cps ml−1. s, Two 
times lower rate of ART interruption. Based on 200 model runs per strategy for 
each of a–s.
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viral-load-informed differentiated care. The effectiveness of such an ap-
proach is unknown, however, and it would lead to some people in whom 
adherence is low and/or resistance is present, and viral load is high, being 
asked to visit clinic less frequently. It is well established that CD4 counts 
can remain high when virological failure is occurring56 and, likewise, that the 
CD4 count can remain low despite full virologic suppression. Thus, the neg-
ative effects of such a strategy would be a concern and, although we did 
model this as a potential strategy (Supplementary Fig. 1j) it is possible that 
we did not fully capture the extent of these negative effects. 
We have largely focussed on use of DBS rather than plasma collection 
as an approach. Although plasma samples from a venepuncture and sample 
separation are an ideal sample, for transport of more than 6–24 hours this 
requires cold temperatures and so the approach is only likely to be applica-
ble in areas for which samples can reach the laboratory in that time. 
Although we have argued that a DBS approach is feasible in most set-
tings, this is not to say that the approach is working well everywhere57. It is 
important that there is investment in improvements to existing systems, in-
cluding diagnostics laboratories and logistics of specimen distribution, and 
we have endeavoured to capture these costs as part of our overall costs of 
delivering viral-load testing using DBS. It is notable that most studies that 
have evaluated viral load using DBS compared with plasma have been per-
formed in a laboratory setting using venepuncture samples and a capillary 
tube (which measures a precise 100 µl whole blood) to fill in the DBS card. 
Few studies are available to assess the performance of DBS in the real-world 
scenario — where it is hot, where sample-transport times are long, where 
venepuncture is not an option, and where samples are from a finger prick 
rather than a capillary tube — although one such study has found encour-
aging findings27. Our finding that viral-load-informed differentiated care is 
cost-effective was robust to low levels of sensitivity or specificity using DBS 
(Fig. 4, Supplementary Fig. 1).
We simplified the comparison of types of viral-load test by breaking 
them down according to whether they are done at POC or in a laboratory 
and whether the sample consisted of whole blood or plasma. We recognise 
that this is something of an oversimplification in that, for example, meas-
urement of viral load by POC testing on whole blood may not always have 
the same sensitivity or specificity as using whole blood in the form of DBS. 
Improved sensitivity and specificity compared with DBS offers a modest, but 
real benefit, as does the ability to measure the viral-load level such that it 
can be acted on in the same day, avoiding a delay until the next visit or the 
need to contact and recall the patient. Even if a POC viral-load test with the 
desirable properties we considered does become available it is likely that 
countries would use a mix of approaches (plasma samples, DBS and POC) 
depending on settings. It should be noted that the cost we assumed for a 
POC assay of $22 was used as a placeholder for the actual cost when this is 
known. It is uncertain whether such tests will be able to be delivered at this 
cost, as a fully-loaded cost, which takes account of staff operator time, and 
our results should be interpreted in the light of this.
If differentiated care can be successfully implemented using viral-load 
monitoring less frequently than every 12 months (for example, every 24 
months) our modelling suggests that less frequent monitoring would be ex-
pected to be cost-effective. However, the health risks of differentiated care 
with such infrequent viral-load monitoring are not well understood and may 
not have been fully captured in our model. Further evidence on whether this 
approach is feasible, and the health consequences of its implementation, is 
required. Only in highly resourced health-care systems (with a cost-effec-
tiveness threshold of more than $1,400 per DALY averted) is more-frequent 
monitoring (for example, every 6 months) expected to be cost-effective. 
We found little evidence to support substantial benefits associated with 
increasing or decreasing the cut-off (viral-load counts >1,000 cps ml−1) at 
which treatment is considered to have failed. A cut-off of 200 cps ml−1 re-
sults in more DALYs being averted — due to identifying people with virolog-
ical failure earlier — but relies on a plasma-based test (and phlebotomy to 
achieve sufficient sample volume) and does not meet the $500 cost-effec-
tiveness threshold.  
Given the role of viral-load testing for enabling reduced visit frequency, it 
should also have a role in people on second-line regimens. When evaluating 
our monitoring strategies we assumed that CD4 count or viral-load tests 
would only be done in patients on first-line treatment, so we may have un-
derstated the benefits of viral-load-informed differentiated care.
We considered whether our base case results would still hold with var-
ious alterations in assumptions and settings. In a scenario in which the pat-
tern of adherence was generally poorer than in our base case (leading to 
68% of people on ART with viral suppression compared with 82% in our 
base case) viral-load-informed differentiated care remained cost-effective. 
This was also true in a scenario with high HIV incidence rate, and scenarios 
with different HIV prevalence and ART coverage, suggesting that our find-
ings should hold in various settings in the region.  
Randomized trials have been performed to compare outcomes from 
CD4 count and viral-load monitoring, and these have not identified signif-
icant differences in outcomes. Such trials have been characterized by rela-
tively short follow-up and low implementation of switching to second-line 
therapy58–64, leading to low power to detect differences.  
We focussed on monitoring for adults. In children and, more likely, ad-
olescents levels of adherence may be lower than in adults. We did find that 
our main findings hold in populations with a tendency for lower adherence. 
However, there may be a greater reluctance to reduce visit frequency as chil-
dren are growing up and constantly facing new challenges and situations and 
clinic staff may wish for regular contact to ensure that these new challenges 
have not led to a drop in adherence. Likewise, there may be a reluctance to 
reduce visit frequency for women in the year or so post-partum. We also 
considered whether monitoring more-intensively — every 6 months rather 
than every 12 months — would be cost-effective for populations with a poor-
er adherence profile (Supplementary Fig. 1t), but this was not the case. Other 
limitations of this work include the fact that we considered a hypothetical 
cohort with simulated outcomes, and future trends are uncertain — particu-
larly in sexual behaviour, levels of male circumcision and adherence to ART. 
Furthermore, we assume continuation of HIV testing and ART availability at 
current trends. The profile of new POC viral-load tests is as yet uncertain, as 
is their cost. However, new diagnostic technologies, including POC viral-load 
testing and beyond, have great potential to enhance delivery of HIV care. We 
have investigated uncertainty through a series of one-way and multi-way 
sensitivity analyses and recognize that there are other approaches, such 
as probabilistic sensitivity analysis and approximate Bayesian computation 
that we intend to pursue in further work.
This work provides insight into how to deliver ART monitoring so that 
it is both effective and cost-effective. As well as providing some specific 
guidance to programmes, it highlights the need to research this area further 
to enable us to continue to understand the attributes of programmes and 
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Figure 5 | Comparison with the current situation. The current situation, CD4 
count (World Health Organization, WHO) monitoring with a low rate of 
switching in those meeting the failure criteria (0.05 per 3 months), and viral-
load-informed differentiated care with switch rate as in our base case (0.5 per 3 
months). DBS, dried blood spot.
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to determine how maximum health gains can be realized for patients with 
the resources available. We find that evidence is sufficient to recommend 
viral-load-informed differentiated care that uses DBS, but that further em-
pirical confirmation as the approach is rolled out would be valuable.
1. Siapka, M., Remme, M., Dayo Obure, C., Maier, C., Dehne, K. L. & Vassall A.  Is there 
scope for cost savings and efficiency gains in HIV services? A systematic review of 
the evidence from low- and middle-income countries. Bull. World Health Organ. 92, 
499–511 (2014). 
2. Tagar, E. et al. Multi-country analysis of treatment costs for HIV/AIDS (MATCH): facili-
ty-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia. 
PLoS ONE 9, e108304 (2014).
3. Menzies, N. A. et al. The cost of providing comprehensive HIV treatment in PEP-
FAR-supported programs. AIDS 25, 1753–1760 (2011).
4. Ware, N. C. et al. Toward an understanding of disengagement from HIV treatment and 
care in sub-Saharan Africa: a qualitative study. PLoS Med. 10, e1001369 (2013).
5. World Health Organisation. Technical and Operational Considerations for Implement-
ing HIV Viral Load Testing. Access to HIV diagnostics (WHO, 2014). 
6. UNAIDS. Landmark HIV Diagnostic Access Program will Save $150m and Help Achieve 
New Global Goals on HIV http://www.unaids.org/en/resources/presscentre/pressre-
leaseandstatementarchive/2014/september/20140925prviralload (UNAIDS, 2014)
7. Phillips, A. N., Pillay, D., Miners, A. H., Bennett, D. E, Gilks, C. F. & Lundgren, J. D. 
Outcomes from monitoring of patients on antiretroviral therapy in resource-limited 
settings with viral load, CD4 cell count, or clinical observation alone: a computer 
simulation model. Lancet 371, 1443–1451 (2008).
8. Estill, J. et al. Viral load monitoring of antiretroviral therapy, cohort viral load and 
HIV transmission in Southern Africa: a mathematical modelling analysis. AIDS 26, 
1403–1413 (2012).
9. Braithwaite, R.S. et al. Alternative antiretroviral monitoring strategies for HIV-in-
fected patients in east Africa: opportunities to save more lives? J. Intl AIDS Soc. 14, 
38 (2011).
10. Kimmel, A.D. et al. Laboratory monitoring to guide switching antiretroviral therapy 
in resource-limited settings: clinical benefits and cost-effectiveness. J. Acquir. Im-
mune Defic. Syndr. 54, 258–268 (2010).
11. Braithwaite, R. S. et al. How do different eligibility guidelines for antiretroviral ther-
apy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? 
AIDS 28 (Suppl 1), S73–S83 (2013). 
12. Estill, J. et al. Monitoring of antiretroviral therapy programmes in Malawi, South 
Africa and Zambia: Mathematical Modelling Study. PLoS ONE 8, e57611.15 (2013).
13. Keebler, D. et al. Cost-effectiveness of different strategies to monitor adults on an-
tiretroviral treatment: a combined analysis of three mathematical models. Lancet 
Glob. Health 2, e35–e43 (2013). 
14. Bendavid, E. et al. Cost-effectiveness of HIV monitoring strategies in resource-limit-
ed settings: a southern African analysis. Arch. Int. Med. 17, 168 (2008).
15. Hamers, R. L., Sawyer, A. W., Tuohy, M., Stevens, W.S., Rinke de Wit, T. F & Hill, A. M. 
Cost-effectiveness of laboratory monitoring for management of HIV treatment in 
sub-Saharan Africa: a model-based analysis. AIDS 26, 1663–1672 (2012).
16. Rutstein, S. E. et al. Dried blood spots for viral load monitoring in Malawi: feasible 
and effective. PLoS ONE 10, e0124748 (2015).
17. Andreotti, M. et al. Correlation between HIV-1 viral load quantification in plasma, 
dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. J. 
Clin. Virol. 47, 4–7 (2010). 
18. Garrido, C. et al. Correlation between human immunodeficiency virus type 1 (HIV-1) 
RNA measurements obtained with dried blood spots and those obtained with plas-
ma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J. Clin. 
Microbiol. 47, 1031–1036 (2009). 
19. Johannessen, A. et al. Dried blood spots perform well in viral load monitoring of 
patients who receive antiretroviral treatment in rural Tanzania. Clin. Infect. Dis. 49, 
976–981 (2009). 
20. Marconi, A. et al. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with 
dried blood spot speci mens. Clin. Microbiol. Infect. 15, 93–97 (2009). 
21. Arredondo, M. et al. Comparison of HIV-1 RNA measurements using plasma and 
dried blood spots (DBS) in the Automated Abbott Real Time Viral Load Assay. J. Clin. 
Microbiol. 50, 569–572 (2011). 
22. Pirillo MF-Pinson, P. et al. Quantification of HIV-RNA from dried blood spots using 
Siemens VERSANT® HIV-1 RNA (kPCR) assay. J. Antimicrob. Chemother. 66, 2823–
2826 (2011).
23. Ondoa, P. et al. Performance and logistical challenges of alternative HIV-1 virolog-
ical monitoring options in a clinical setting of Harare, Zimbabwe. BioMed Res. Int. 
2014, 102598 (2014).
24. Fajardo, E. et al. Prospective evaluation of diagnostic accuracy of dried blood spots 
from finger prick samples for determination of HIV-1 Load with the NucliSENS 
Easy-Q HIV-1 version 2.0 Assay in Malawi. J. Clinical Microbiol. 52, 1343–1351 (2014).
25. Smit, P. W. et al. Systematic review of the use of dried blood spots for monitoring HIV 
viral load and for early infant diagnosis. PLoS ONE 9, e86461 (2014).
26. Rutstein, E. et al. Measures of viral load using Abbott RealTime HIV-1 Assay on ve-
nousand fingerstick dried blood spots from provider-collected specimens in Ma-
lawian District Hospitals. J. Clin. Virol. 60, 392–398 (2014).
27. Mavedzenge, S. N. et al. Finger prick dried blood spots for HIV viral load measure-
ment in field conditions in Zimbabwe. PloS ONE 10, e0126878 (2015).
100 
200 
300 
500 
400 
600 
800 
700 
900 
DALYs averted 
0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000
"!
ICER = $326 
12 monthly 
Frequency of testing 12 monthly versus 6 monthly and 2 yearly
In context of viral load measurement using lab - 
whole blood (DBS) and 1,000 cps ml–1 threshold    
Laboratory testing (3 month delay) versus POC 
Whole blood versus plasma sample 
In context of 12-monthly viral-load measurement 
and 1,000 cpy ml–1 threshold 
Viral load threshold for switching: 200, 1,000 and 
5,000 cps ml–1 
In context of 12-monthly viral-load measurement 
using lab plasma
2 yearly
6 monthly 
ICER = $1234
"!
ICER = $293 
POC -
plasma   
POC -
whole 
blood  
Lab -
plasma   
Lab -
whole
blood
(DBS)   
"!
ICER = $311 
200 
1,000 
5,000 
ICER = $350 
ICER = $687 
No
monitoring 
100 
200 
300 
500 
400 
600 
800 
700 
900 
DALYs averted 
0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000
No
monitoring 
100 
200 
300 
500 
400 
600 
800 
700 
900 
DALYs averted 
0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000
No
monitoring 
a
b
c
Figure 6 | Cost-effectiveness planes showing the effect of viral load measure-
ment frequency, format and threshold, all in the context of viral-load-informed 
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